Header Logo

Connection

Gary Raskob to Venous Thromboembolism

Back to Details
This is a "connection" page, showing publications Gary Raskob has written about Venous Thromboembolism.
Gary Raskob
Connection Strength
19.692
Venous Thromboembolism
  1. Unmet Needs and Challenges in Cancer-Associated Venous Thromboembolism. Int J Mol Sci. 2026 Feb 12; 27(4).
    View in: PubMed
    Score: 0.831
  2. Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials. Lancet. 2025 Nov 29; 406(10519):2551-2563.
    View in: PubMed
    Score: 0.816
  3. Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness. J Am Heart Assoc. 2022 10 18; 11(20):e026229.
    View in: PubMed
    Score: 0.659
  4. Cancer-associated venous thromboembolism: Incidence and features in a racially diverse population. J Thromb Haemost. 2022 10; 20(10):2366-2378.
    View in: PubMed
    Score: 0.651
  5. Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. J Am Heart Assoc. 2021 11 16; 10(22):e021579.
    View in: PubMed
    Score: 0.619
  6. Incidence of Venous Thromboembolism in a Racially Diverse Population of Oklahoma County, Oklahoma. Thromb Haemost. 2021 Jun; 121(6):816-825.
    View in: PubMed
    Score: 0.584
  7. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. Oncologist. 2021 01; 26(1):e8-e16.
    View in: PubMed
    Score: 0.580
  8. Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. J Am Coll Cardiol. 2020 06 30; 75(25):3140-3147.
    View in: PubMed
    Score: 0.563
  9. Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. Thromb Haemost. 2020 Jun; 120(6):924-936.
    View in: PubMed
    Score: 0.560
  10. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA. 2020 01 14; 323(2):130-139.
    View in: PubMed
    Score: 0.545
  11. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study. Thromb Res. 2020 01; 185:13-19.
    View in: PubMed
    Score: 0.538
  12. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost. 2019 11; 17(11):1866-1874.
    View in: PubMed
    Score: 0.528
  13. Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. Clin Appl Thromb Hemost. 2019 Jan-Dec; 25:1076029619886022.
    View in: PubMed
    Score: 0.508
  14. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thromb Haemost. 2018 Aug; 118(8):1439-1449.
    View in: PubMed
    Score: 0.493
  15. Edoxaban for Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 07 05; 379(1):95-96.
    View in: PubMed
    Score: 0.490
  16. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 Feb 15; 378(7):615-624.
    View in: PubMed
    Score: 0.472
  17. New paradigms in venous thromboprophylaxis of medically ill patients. Thromb Haemost. 2017 08 30; 117(9):1662-1670.
    View in: PubMed
    Score: 0.457
  18. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016 Aug; 3(8):e379-87.
    View in: PubMed
    Score: 0.427
  19. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 May; 3(5):e228-36.
    View in: PubMed
    Score: 0.419
  20. Global public awareness of venous thromboembolism: reply. J Thromb Haemost. 2016 05; 14(5):1111-2.
    View in: PubMed
    Score: 0.417
  21. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost. 2016 06 02; 115(6):1240-8.
    View in: PubMed
    Score: 0.415
  22. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thromb Haemost. 2016 Apr; 115(4):809-16.
    View in: PubMed
    Score: 0.410
  23. The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. Thromb Res. 2016 Jan; 137:3-10.
    View in: PubMed
    Score: 0.409
  24. The design and implementation of a new surveillance system for venous thromboembolism using combined active and passive methods. Am Heart J. 2015 Sep; 170(3):447-54.e18.
    View in: PubMed
    Score: 0.397
  25. Oral anticoagulants: new and improved. Blood. 2014 Sep 18; 124(12):1851-2.
    View in: PubMed
    Score: 0.377
  26. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. J Thromb Haemost. 2013 Jul; 11(7):1287-94.
    View in: PubMed
    Score: 0.347
  27. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br. 2012 Feb; 94(2):257-64.
    View in: PubMed
    Score: 0.314
  28. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost. 2010 Sep; 104(3):642-9.
    View in: PubMed
    Score: 0.281
  29. Exclusion of first-episode deep-vein thrombosis after-hours using D-dimer. Blood Coagul Fibrinolysis. 2007 Dec; 18(8):795-800.
    View in: PubMed
    Score: 0.235
  30. Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score. Eur Heart J. 2023 04 07; 44(14):1231-1244.
    View in: PubMed
    Score: 0.170
  31. Redefining clinical venous thromboembolism phenotypes: a?novel approach using latent class analysis. J Thromb Haemost. 2023 03; 21(3):573-585.
    View in: PubMed
    Score: 0.167
  32. Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. Circulation. 2022 05 10; 145(19):1471-1479.
    View in: PubMed
    Score: 0.159
  33. Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med. 2021 12 02; 385(23):2161-2172.
    View in: PubMed
    Score: 0.155
  34. Abelacimab for Prevention of Venous Thromboembolism. Reply. N Engl J Med. 2021 11 04; 385(19):1822-1823.
    View in: PubMed
    Score: 0.155
  35. Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis. Ann Intern Med. 2021 10; 174(10):1420-1429.
    View in: PubMed
    Score: 0.153
  36. Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. J Thromb Haemost. 2021 12; 19(12):3008-3017.
    View in: PubMed
    Score: 0.153
  37. Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. J Thromb Haemost. 2021 11; 19(11):2801-2813.
    View in: PubMed
    Score: 0.152
  38. Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. J Thromb Haemost. 2021 11; 19(11):2772-2780.
    View in: PubMed
    Score: 0.152
  39. Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med. 2021 08 12; 385(7):609-617.
    View in: PubMed
    Score: 0.151
  40. Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis. Clin Appl Thromb Hemost. 2021 Jan-Dec; 27:10760296211053316.
    View in: PubMed
    Score: 0.146
  41. Clinical implications of incidental venous thromboembolism in cancer patients. Eur Respir J. 2020 02; 55(2).
    View in: PubMed
    Score: 0.137
  42. Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis. Thromb Res. 2019 Dec; 184:58-61.
    View in: PubMed
    Score: 0.134
  43. Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis. J Thromb Haemost. 2019 12; 17(12):2081-2088.
    View in: PubMed
    Score: 0.134
  44. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. Thromb Haemost. 2019 Mar; 119(3):461-466.
    View in: PubMed
    Score: 0.127
  45. Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 12 06; 379(23):2280.
    View in: PubMed
    Score: 0.126
  46. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 Sep 20; 379(12):1118-1127.
    View in: PubMed
    Score: 0.124
  47. The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. Thromb Res. 2018 10; 170:75-83.
    View in: PubMed
    Score: 0.124
  48. Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2018 Jul; 118(7):1270-1278.
    View in: PubMed
    Score: 0.122
  49. Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients. Thromb Haemost. 2018 01; 118(1):174-181.
    View in: PubMed
    Score: 0.118
  50. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. Thromb Res. 2018 02; 162:7-14.
    View in: PubMed
    Score: 0.118
  51. Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2017 12; 117(12):2406-2414.
    View in: PubMed
    Score: 0.118
  52. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. Thromb Haemost. 2017 Oct; 117(10):1944-1951.
    View in: PubMed
    Score: 0.118
  53. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis. Thromb Haemost. 2017 10 05; 117(10):1944-1951.
    View in: PubMed
    Score: 0.115
  54. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists. Thromb Haemost. 2017 04 03; 117(4):784-793.
    View in: PubMed
    Score: 0.111
  55. RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. Thromb Haemost. 2017 01 26; 117(2):415-421.
    View in: PubMed
    Score: 0.110
  56. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 Sep; 3(9):e437-45.
    View in: PubMed
    Score: 0.108
  57. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. Thromb Haemost. 2016 Nov 30; 116(6):1159-1164.
    View in: PubMed
    Score: 0.108
  58. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thromb Haemost. 2016 Sep 27; 116(4):747-53.
    View in: PubMed
    Score: 0.107
  59. Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension. Chest. 2016 Nov; 150(5):1059-1068.
    View in: PubMed
    Score: 0.106
  60. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thromb Haemost. 2016 07 04; 116(1):155-61.
    View in: PubMed
    Score: 0.105
  61. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015 Dec; 13(12):2187-91.
    View in: PubMed
    Score: 0.102
  62. Global public awareness of venous thromboembolism. J Thromb Haemost. 2015 Aug; 13(8):1365-71.
    View in: PubMed
    Score: 0.100
  63. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10; 369(15):1406-15.
    View in: PubMed
    Score: 0.088
  64. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29; 369(9):799-808.
    View in: PubMed
    Score: 0.087
  65. Prevention and treatment of venous thromboembolism--International Consensus Statement. Int Angiol. 2013 Apr; 32(2):111-260.
    View in: PubMed
    Score: 0.085
  66. Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. J Thromb Haemost. 2013 Mar; 11(3):444-51.
    View in: PubMed
    Score: 0.085
  67. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 02 21; 368(8):699-708.
    View in: PubMed
    Score: 0.083
  68. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ. 2011 May 24; 342:d3036.
    View in: PubMed
    Score: 0.075
  69. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 Dec 23; 363(26):2487-98.
    View in: PubMed
    Score: 0.073
  70. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost. 2010 Dec; 104(6):1150-7.
    View in: PubMed
    Score: 0.072
  71. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 Mar 06; 375(9717):807-15.
    View in: PubMed
    Score: 0.069
  72. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 Aug 06; 361(6):594-604.
    View in: PubMed
    Score: 0.066
  73. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009 Apr; 101(4):762-9.
    View in: PubMed
    Score: 0.065
  74. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 Jan; 24(1):1-9.
    View in: PubMed
    Score: 0.060
  75. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007 Dec 01; 25(34):5490-505.
    View in: PubMed
    Score: 0.058
  76. Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. Thromb Haemost. 2020 Mar; 120(3):515-524.
    View in: PubMed
    Score: 0.034
  77. The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thromb Haemost. 2019 Jan; 119(1):14-38.
    View in: PubMed
    Score: 0.032
  78. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23; 363(26):2499-510.
    View in: PubMed
    Score: 0.018
  79. Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med. 2009 Aug; 122(8):762-769.e3.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.